These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 24735395)
1. The Kv7 potassium channel activator retigabine decreases alcohol consumption in rats. Knapp CM; O'Malley M; Datta S; Ciraulo DA Am J Drug Alcohol Abuse; 2014 May; 40(3):244-50. PubMed ID: 24735395 [TBL] [Abstract][Full Text] [Related]
2. Kv7 channels in the nucleus accumbens are altered by chronic drinking and are targets for reducing alcohol consumption. McGuier NS; Griffin WC; Gass JT; Padula AE; Chesler EJ; Mulholland PJ Addict Biol; 2016 Nov; 21(6):1097-1112. PubMed ID: 26104325 [TBL] [Abstract][Full Text] [Related]
3. Inhibitory effects of retigabine, a Kv7 channel activator, on mechanosensitive primary bladder afferent activities and nociceptive behaviors in rats. Aizawa N; Wakamatsu D; Kida J; Otsuki T; Saito Y; Matsuya H; Homma Y; Igawa Y Neurourol Urodyn; 2017 Feb; 36(2):280-285. PubMed ID: 26536146 [TBL] [Abstract][Full Text] [Related]
4. The pan-Kv7 (KCNQ) Channel Opener Retigabine Inhibits Striatal Excitability by Direct Action on Striatal Neurons In Vivo. Hansen HH; Weikop P; Mikkelsen MD; Rode F; Mikkelsen JD Basic Clin Pharmacol Toxicol; 2017 Jan; 120(1):46-51. PubMed ID: 27377794 [TBL] [Abstract][Full Text] [Related]
5. Differential potassium channel gene regulation in BXD mice reveals novel targets for pharmacogenetic therapies to reduce heavy alcohol drinking. Rinker JA; Fulmer DB; Trantham-Davidson H; Smith ML; Williams RW; Lopez MF; Randall PK; Chandler LJ; Miles MF; Becker HC; Mulholland PJ Alcohol; 2017 Feb; 58():33-45. PubMed ID: 27432260 [TBL] [Abstract][Full Text] [Related]
6. Activation of KCNQ channels located on the skeletal muscle membrane by retigabine and its influence on the maximal muscle force in rat muscle strips. Zagorchev P; Apostolova E; Kokova V; Peychev L Naunyn Schmiedebergs Arch Pharmacol; 2016 Apr; 389(4):439-46. PubMed ID: 26815201 [TBL] [Abstract][Full Text] [Related]
7. Cardiovascular responses to retigabine in conscious rats--under normotensive and hypertensive conditions. Fretwell LV; Woolard J Br J Pharmacol; 2013 Jul; 169(6):1279-89. PubMed ID: 23581476 [TBL] [Abstract][Full Text] [Related]
8. The novel dual-mechanism Kv7 potassium channel/TSPO receptor activator GRT-X is more effective than the Kv7 channel opener retigabine in the 6-Hz refractory seizure mouse model. Bloms-Funke P; Bankstahl M; Bankstahl J; Kneip C; Schröder W; Löscher W Neuropharmacology; 2022 Feb; 203():108884. PubMed ID: 34785163 [TBL] [Abstract][Full Text] [Related]
9. K Urena ES; Diezel CC; Serna M; Hala'ufia G; Majuta L; Barber KR; Vanderah TW; Riegel AC Addict Biol; 2024 Aug; 29(8):e13428. PubMed ID: 39087789 [TBL] [Abstract][Full Text] [Related]
11. The anti-hyperalgesic activity of retigabine is mediated by KCNQ potassium channel activation. Dost R; Rostock A; Rundfeldt C Naunyn Schmiedebergs Arch Pharmacol; 2004 Apr; 369(4):382-90. PubMed ID: 15007538 [TBL] [Abstract][Full Text] [Related]
12. The neuronal KCNQ channel opener retigabine inhibits locomotor activity and reduces forebrain excitatory responses to the psychostimulants cocaine, methylphenidate and phencyclidine. Hansen HH; Andreasen JT; Weikop P; Mirza N; Scheel-Krüger J; Mikkelsen JD Eur J Pharmacol; 2007 Sep; 570(1-3):77-88. PubMed ID: 17628530 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of striatal cholinergic interneuron activity by the Kv7 opener retigabine and the nonsteroidal anti-inflammatory drug diclofenac. Paz RM; Tubert C; Stahl A; Díaz AL; Etchenique R; Murer MG; Rela L Neuropharmacology; 2018 Jul; 137():309-321. PubMed ID: 29758221 [TBL] [Abstract][Full Text] [Related]
14. The anticonvulsant retigabine suppresses neuronal K Stas JI; Bocksteins E; Jensen CS; Schmitt N; Snyders DJ Sci Rep; 2016 Oct; 6():35080. PubMed ID: 27734968 [TBL] [Abstract][Full Text] [Related]
15. Anxiolytic effects of Maxipost (BMS-204352) and retigabine via activation of neuronal Kv7 channels. Korsgaard MP; Hartz BP; Brown WD; Ahring PK; Strøbaek D; Mirza NR J Pharmacol Exp Ther; 2005 Jul; 314(1):282-92. PubMed ID: 15814569 [TBL] [Abstract][Full Text] [Related]
16. The KCNQ channel activator retigabine blocks haloperidol-induced c-Fos expression in the striatum of the rat. Mikkelsen JD Neurosci Lett; 2004 May; 362(3):240-3. PubMed ID: 15158023 [TBL] [Abstract][Full Text] [Related]
17. Activation of KCNQ Channels Suppresses Spontaneous Activity in Dorsal Root Ganglion Neurons and Reduces Chronic Pain after Spinal Cord Injury. Wu Z; Li L; Xie F; Du J; Zuo Y; Frost JA; Carlton SM; Walters ET; Yang Q J Neurotrauma; 2017 Mar; 34(6):1260-1270. PubMed ID: 28073317 [TBL] [Abstract][Full Text] [Related]
18. Antinociceptive Efficacy of Retigabine in the Monosodium Lodoacetate Rat Model for Osteoarthritis Pain. Li H; Wang F; Wang X; Sun R; Chen J; Chen B; Zhang Y Pharmacology; 2015; 95(5-6):251-7. PubMed ID: 25997526 [TBL] [Abstract][Full Text] [Related]
19. Activation of K Djouhri L; Malki MI; Zeidan A; Nagi K; Smith T J Drug Target; 2019 Dec; 27(10):1118-1126. PubMed ID: 30995134 [TBL] [Abstract][Full Text] [Related]
20. Treatment of myotonia congenita with retigabine in mice. Dupont C; Denman KS; Hawash AA; Voss AA; Rich MM Exp Neurol; 2019 May; 315():52-59. PubMed ID: 30738808 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]